Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1 + mRNA-1273 + BNT162b2
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination of three different COVID-19 vaccines: ChAdOx1 (Oxford/AstraZeneca), mRNA-1273 (Moderna), and BNT162b2 (Pfizer-BioNTech). These are not typically administered together as a single combination product but may be used in heterologous vaccination schedules (mix-and-match approach). ChAdOx1 is a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. BNT162b2 is an mRNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. Both vaccines stimulate the immune system to produce antibodies and activate T cells to protect against COVID-19.
- Brand names
- VaxzevriaComirnaty
- Other names
- Oxford/AstraZeneca COVID-19 VaccinePfizer-BioNTech COVID-19 Vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ChAdOx1 + mRNA-1273 + BNT162b2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1 + mRNA-1273 + BNT162b2.